***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND Hypertension is a common toxicity of bevacizumab , but the frequency of assessment of blood pressure and st and ardized grading remain to be defined . This study aim ed to describe the incidence of bevacizumab-induced hypertension and factors associated with its development , then to retrospectively assess its relation with activity . PATIENTS AND METHODS One hundred nineteen patients with advanced or metastatic non-small cell lung cancer , colorectal cancer , or ovarian cancer receiving bevacizumab ( 2.5 mg/kg per week ) and chemotherapy  were eligible for this analysis .  Blood pressure  was measured at home twice daily according to international guidelines , and grade d according to the National Cancer Institute Common Toxicity Criteria ( NCI-CTC ) , version 3.0 , and the European Society of Hypertension ( ESH ) criteria . RESULTS Home-based measurements detected significantly more cases of hypertension than in-clinic measurements did , according to the ESH criteria ( 54.6 % versus 24.4 % ; p < .001 ) or the NCI-CTC ( 42.9 % versus 22.7 % ; p = .0015 ) . Very early hypertension ( within 42 days , according to the ESH criteria ) but not hypertension ( occurring at any time during treatment period ) was predictive of response ( p = .0011 and p = .26 , respectively ) . CONCLUSIONS Our preliminary results indicate that home-based measurement and grading according to the ESH criteria represents a reliable method to detect bevacizumab-induced hypertension . Whether hypertension is a biomarker of bevacizumab activity remains to be determined in a prospect i ve study OBJECTIVE We examined the safety and efficacy of combining bevacizumab with albumin-bound ( ab- ) paclitaxel to treat patients with recurrent , platinum-resistant primary epithelial ovarian or peritoneal carcinoma . METHODS Patients had measurable disease per RECIST guidelines , progressing within 6 months after a prior course of platinum-based treatment . Patients received ab-paclitaxel 100mg/m(2 ) given by intravenous infusion over 30 min on days 1 , 8 , and 15 of a 28-day cycle with bevacizumab 10mg/kg given on days 1 and 15 . RESULTS Forty-eight patients with an average 1.8 prior lines of treatment participated . The overall response rate was 50 % ( 24/48 ) ( 95 % CI , 34.8 % - 65.1 % ) , with 4 complete and 20 partial responses . Fourteen patients ( 29 % ) had stable disease , whereas eight ( 17 % ) had progressive disease , and two ( 4 % ) were not evaluable . Patients received a median of 6 treatment cycles ( range , 1 - 31 cycles ) . The median progression-free survival was 8.08 months ( 95 % CI , 5.78 - 10.15 months ) ; 6 month progression-free rate was 62.5 % ( 95 % CI , 47.8%-77.2 % ) ; median overall survival was 17.15 months ( 95 % CI , 13.57 - 23.82 months ) . Grade 3 - 4 adverse events included gastrointestinal disorders ( 18.8 % ) , neutropenia ( 8.3 % ) , and hypertension ( 6.3 % ) . CONCLUSIONS Ab-paclitaxel with bevacizumab clearly demonstrates antitumor activity and manageable toxicity profile in patients with recurrent , platinum-resistant ovarian carcinoma . This regimen should be evaluated in a larger r and omized trial BACKGROUND Treatment with cetuximab , a monoclonal antibody directed against the epidermal growth factor receptor , improves overall and progression-free survival and preserves the quality of life in patients with colorectal cancer that has not responded to chemotherapy . The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value . METHODS We analyzed tumor sample s , obtained from 394 of 572 patients ( 68.9 % ) with colorectal cancer who were r and omly assigned to receive cetuximab plus best supportive care or best supportive care alone  , to look for activating mutations in exon 2 of the K-ras gene . We assessed whether the mutation status of the K-ras gene was associated with survival in the cetuximab and supportive-care groups . RESULTS Of the tumors evaluated for K-ras mutations , 42.3 % had at least one mutation in exon 2 of the gene . The effectiveness of cetuximab was significantly associated with K-ras mutation status ( P=0.01 and P<0.001 for the interaction of K-ras mutation status with overall survival and progression-free survival , respectively ) . In patients with wild-type K-ras tumors , treatment with cetuximab as compared with supportive care alone significantly improved overall survival ( median , 9.5 vs. 4.8 months ; hazard ratio for death , 0.55 ; 95 % confidence interval [ CI ] , 0.41 to 0.74 ; P<0.001 ) and progression-free survival ( median , 3.7 months vs. 1.9 months ; hazard ratio for progression or death , 0.40 ; 95 % CI , 0.30 to 0.54 ; P<0.001 ) . Among patients with mutated K-ras tumors , there was no significant difference between those who were treated with cetuximab and those who received supportive care alone with respect to overall survival ( hazard ratio , 0.98 ; P=0.89 ) or progression-free survival ( hazard ratio , 0.99 ; P=0.96 ) . In the group of patients receiving best supportive care alone , the mutation status of the K-ras gene was not significantly associated with overall survival ( hazard ratio for death , 1.01 ; P=0.97 ) . CONCLUSIONS Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab , whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab . The mutation status of the K-ras gene had no influence on survival among patients treated with best supportive care alone . ( Clinical Trials.gov number , NCT00079066 . PURPOSE No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer . Vascular endothelial growth factor ( VEGF ) genetic variability has been associated with altered risk of breast cancer and variable promoter activity . Therefore , we evaluated the association of VEGF genotype with efficacy and toxicity in E2100 , a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer . PATIENTS AND METHODS DNA was extracted from tumor blocks of patients from E2100 . Three hundred sixty-three sample s were available to evaluate associations between genotype and outcome . Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2 . Testing for associations between each polymorphism and efficacy and toxicity was performed . RESULTS The VEGF-2578 AA genotype was associated with a superior median overall survival ( OS ) in the combination arm when compared with the alternate genotypes combined ( hazard ratio = 0.58 ; 95 % CI , 0.36 to 0.93 ; P = .023 ) . The VEGF-1154 A allele also demonstrated a superior median OS with an additive effect of each active allele in the combination arm but not the control arm ( hazard ratio = 0.62 ; 95 % CI , 0.46 to 0.83 ; P = .001 ) . Two additional genotypes , VEGF-634 CC and VEGF-1498 TT , were associated with significantly less grade 3 or 4 hypertension in the combination arm when compared with the alternate genotypes combined ( P = .005 and P = .022 , respectively ) . CONCLUSION Our data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer 
    Output:
    
Conclusions Bevacizumab-induced hypertension may represent a prognostic factor in patients with metastatic colorectal cancer